EXCLI J EXCLI Journal 1611-2156 Leibniz Research Centre for Working Environment and Human Factors 2015-758 10.17179/excli2015-758 Doc1259 Editorial material Transcriptomic signature for drug-induced steatosis Stöber Regina * 1 Leibniz Research Centre for Working Environment and Human Factors at TU Dortmund (IfADo), Ardeystrasse 67, 44139 Dortmund, Germany *To whom correspondence should be addressed: Regina Stöber, Leibniz Research Centre for Working Environment and Human Factors at TU Dortmund (IfADo), Ardeystrasse 67, 44139 Dortmund, Germany, E-mail: stoeber@ifado.de 21 12 2015 2015 14 1259 1260 23 11 2015 11 12 2015 Copyright © 2015 Stöber 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0/) You are free to copy, distribute and transmit the work, provided the original author and source are credited.

 This article is available from http://www.excli.de/vol14/Stoeber_21122015_proof.pdf 

Non-alcoholic fatty liver disease (NAFLD) affects almost one third of adults in European countries. A well-known factor of influence is overnutrition and insulin resistance (Farrell and Larter, 2006[7]). In contrast, much less attention is given to drug induced steatosis (Chen et al., 2014[4]). It is crucial that steatosis inducing compounds are detected and excluded early in drug development (Hewitt et al., 2007[16]; Hengstler et al., 2000[15]; Vitins et al., 2014[20]; Fisher et al., 2008[8]; Rogiers et al., 1997[19]).

Recently, Marta Benet and colleagues from Barcelona and Valenica in Spain have published a transcriptomic signature to identify compounds with an increased risk of inducing steatosis (Benet et al., 2014[2]). Numerous mechanisms can cause steatosis. Many steatosis-inducing drugs impair fatty acid beta-oxidation (FAO) by inhibiting involved enzymes or by blocking the transport of fatty acids into mitochondria.

Moreover, compromising the mitochondrial respiratory chain or mitochondrial potential may indirectly cause steatosis (Benet al., 2014[2]; Donato and Gomez-Lechon, 2012[5]; Fromenty and Pessayre, 1995[9]). One possibility to study the potential to induce steatosis is to quantify the levels of neutral lipids, e.g. by BODIPY or oil red O staining. However, these techniques have been reported to be relatively insensitive (Benet et al., 2014[2]). In their recent publication Benet and colleagues (2014[2]) have established a common signature of three transcription factors: FOXA1, HEX and SREBP1C. Totally, 25 well-characterized compounds were studied in HepG2 cells. Using the aforementioned transcription factors as biomarkers, 92 % of the test compounds were correctly classified (Benet et al., 2014[2]). Currently much effort is invested in research on hepatotoxic mechanisms (Onami et al., 2014[18]; Campos et al., 2014[3]; An, 2012[1]; Fang et al., 2012[6]; Monteiro et al., 2013[17]) and in vitro systems to predict hepatotoxicity (Godoy et al., 2015[14], 2013[13], 2009[12]; Zellmer et al., 2010[21]; Ghallab, 2014[11][10]).

In this context the identification of the steatogenic FOXA1/HEX/SREBP1C signature by Benet and colleagues (2014[2]) represents an important progress and should be included into predictive studies in future.

 An L Wang X Cederbaum AI Cytokines in alcoholic liver disease Arch Toxicol 2012 86 1337 1348 Benet M Moya M Donato MT Lahoz A Hervás D Guzmán C A simple transcriptomic signature able to predict drug-induced hepatic steatosis Arch Toxicol 2014 88 967 982 Campos G Schmidt-Heck W Ghallab A Rochlitz K Pütter L Medinas DB The transcription factor CHOP, a central component of the transcriptional regulatory network induced upon CCl4 intoxication in mouse liver, is not a critical mediator of hepatotoxicity Arch Toxicol 2014 88 1267 1280 Chen M Tung CW Shi Q Guo L Shi L Fang H A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the 'rule-of-two' model Arch Toxicol 2014 88 1439 1449 Donato MT Gómez-Lechón MJ Drug-induced liver steatosis and phospholipidosis: cell-based assays for early screening of drug candidates Curr Drug Metab 2012 13 1160 1173 Fang X Zou S Zhao Y Cui R Zhang W Hu J Kupffer cells suppress perfluorononanoic acid-induced hepatic peroxisome proliferator-activated receptor α expression by releasing cytokines Arch Toxicol 2012 86 1515 1525 Farrell GC Larter CZ Nonalcoholic fatty liver disease: from steatosis to cirrhosis Hepatology 2006 43 Suppl 1 S99 112 Fisher CD Jackson JP Lickteig AJ Augustine LM Cherrington NJ Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis Arch Toxicol 2008 82 959 964 Fromenty B Pessayre D Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity Pharmacol Ther 1995 67 101 154 Ghallab A Human non-parenchymal liver cells for co-cultivation systems EXCLI J 2014 13 1295 1296 Ghallab A The rediscovery of HepG2 cells for prediction of drug induced liver injury (DILI) EXCLI J 2014 13 1286 1288 Godoy P Hengstler JG Ilkavets I Meyer C Bachmann A Müller A Extracellular matrix modulates sensitivity of hepatocytes to fibroblastoid dedifferentiation and transforming growth factor β-induced apoptosis Hepatology 2009 49 2031 2043 Godoy P Hewitt NJ Albrecht U Andersen ME Ansari N Bhattacharya S Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME Arch Toxicol 2013 87 1315 1530 Godoy P Schmidt-Heck W Natarajan K Lucendo-Villarin B Szkolnicka D Asplund A Gene networks and transcription factor motifs defining the differentiation of stem cells into hepatocyte-like cells J Hepatol 2015 63 934 942 Hengstler JG Utesch D Steinberg P Platt KL Diener B Ringel M Cryopreserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme induction Drug Metab Rev 2000 32 81 118 Hewitt NJ Lechón MJ Houston JB Hallifax D Brown HS Maurel P Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies Drug Metab Rev 2007 39 159 234 Monteiro JP Pereira CV Silva AM Maciel E Baldeiras I Peixoto F Rapeseed oil-rich diet alters hepatic mitochondrial membrane lipid composition and disrupts bioenergetics Arch Toxicol 2013 87 2151 2163 Onami S Cho YM Toyoda T Mizuta Y Yoshida M Nishikawa A A 13-week repeated dose study of three 3-monochloropropane-1,2-diol fatty acid esters in F344 rats Arch Toxicol 2014 88 871 880 Rogiers V Vandenberghe Y Vanhaecke T Geerts A Callaerts A Carleer J Observation of hepatotoxic effects of 2-n-pentylaminoacetamide (Milacemide) in rat liver by a combined in vivo/in vitro approach Arch Toxicol 1997 71 271 282 Vitins AP Kienhuis AS Speksnijder EN Roodbergen M Luijten M van der Ven LT Mechanisms of amiodarone and valproic acid induced liver steatosis in mouse in vivo act as a template for other hepatotoxicity models Arch Toxicol 2014 88 1573 1588 Zellmer S Schmidt-Heck W Godoy P Weng H Meyer C Lehmann T Transcription factors ETF, E2F, and SP-1 are involved in cytokine-independent proliferation of murine hepatocytes Hepatology 2010 52 2127 2136